Combinations or Single Agents, Crossover or No Crossover: Considering Chemotherapy Strategies in the Multi-Chaptered Story of Metastatic Breast Cancer

Published: Nov. 14, 2011, 5:22 p.m.

This podcast will critically review randomized phase III trial data examining the relative role of taxane monotherapy versus combination therapy as first-line treatment for HER2-negative metastatic breast cancer.